Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $232

Jazz Pharmaceuticals Public Limited Company +0.02%

Jazz Pharmaceuticals Public Limited Company

JAZZ

194.23

+0.02%

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Overweight and raises the price target from $219 to $232.